SCHEMBL5161656

SCHEMBL5161656

Cc1c(-c2ccc(Br)cc2)c(=O)oc2ccc(O)cc12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERAP1 Q9NZ08 1/20 0.59
NPC1 O15118 2/20 0.57
ESR1 P03372 5/20 0.51
ESR2 Q92731 4/20 0.51
MIF P14174 1/20 0.50
HSD17B3 P37058 1/20 0.48
CSNK2A2 P19784 2/20 0.47
CSNK2B P67870 2/20 0.47
CSNK2A1 P68400 2/20 0.47
MAOB P27338 2/20 0.45
CYP3A4 P08684 2/20 0.44
MAPT P10636 2/20 0.44
LMNA P02545 1/20 0.44
TP53 P04637 1/20 0.44
THRB P10828 1/20 0.44
HPGD P15428 1/20 0.44
ALOX15 P16050 1/20 0.44
CASP3 P42574 1/20 0.44
RAB9A P51151 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7113502 0.89 ERAP1 (0.75) ERAP1NPC1ESR1ESR2MIF
SCHEMBL5425943 0.86 ERAP1 (0.79) ERAP1NPC1ESR1ESR2HSD17B3
SCHEMBL4267946 0.84 NPC1 (0.81) ERAP1NPC1ESR1ESR2MIF
SCHEMBL7152314 0.81 CA12 (0.45) ERAP1NPC1ESR2CSNK2A2CSNK2B
SCHEMBL5424524 0.81 ERAP1 (0.56) ERAP1NPC1ESR1ESR2HSD17B3
SCHEMBL3091877 0.80 ERAP1 (0.58) ERAP1NPC1MAOBCYP3A4MAPT
SCHEMBL5088627 0.80 ERAP1 (0.83) ERAP1NPC1ESR1ESR2HSD17B3
SCHEMBL27736903 0.80 ERAP1 (0.58) ERAP1NPC1ESR1ESR2HSD17B3
SCHEMBL10847401 0.79 HSD17B3 (0.56) ERAP1ESR1ESR2HSD17B3CSNK2A2
SCHEMBL5423277 0.79 FYN (0.62) ERAP1NPC1ESR2CSNK2A2CSNK2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007115181-A9 COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF EASTMAN CHEM CO (US) 2008-04-03 WO disclosed
US-20070254859-A1 Compounds exhibiting efflux inhibitor activity and composition and uses thereof EASTMAN CHEMICAL COMPANY 2007-11-01 US disclosed
WO-2007115181-A2 COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF EASTMAN CHEMICAL COMPANY (US) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254859-A1 Compounds exhibiting efflux inhibitor activity and composition and uses thereof ABCC4, NCOA4, NR4A3 ERAP1 2734/4885NPC1 362/4885ESR1 258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.